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hormones remained elevated in the second DEX/CRH test, 
despite a reduction in depressive symptoms.  Conclusions: 
This study provides evidence that, depending on gender 
and polymorphisms, there is continuous HPA axis overdrive 
in a proportion of patients irrespective of the status of de-
pression. Considering the importance of stress hormones for 
cardiovascular disorders, our data might suggest that these 
patients are at high risk of comorbidity between depression 
and cardiovascular disorders.  Copyright © 2008 S. Karger AG, Basel 
 Introduction 
 There is substantial evidence that alterations within 
neuroendocrine systems play a major role in complex 
stress-related psychiatric and somatic disorders. Dys-
functions of the hypothalamic-pituitary-adrenal (HPA) 
axis, with enhanced releases of corticotrophin-releasing 
hormone (CRH), adrenocorticotropin (ACTH) and cor-
tisol, influence many functions of the central nervous 
system, such as arousal, cognition, sleep, the mainte-
nance of a normal cardiovascular tone, as well as the ac-
tivity and quality of immune and inflammatory reac-
tions  [1] . On the other hand, cortisol hypersecretion may 
also enhance the central accumulation of body fat, dys-
lipidaemia or hypertension  [2, 3] . Thus, dysregulations 
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 Abstract 
 Objective: There is overwhelming evidence that activation 
of the hypothalamic-pituitary-adrenal (HPA) system plays a 
major role in depression and cardiovascular disease in ge-
netically susceptible individuals. We hypothesized that due 
to the multiple interactions between the sympathetic and 
the HPA systems via adrenoceptors, polymorphisms in these 
genes could have an impact on HPA axis activity in major 
depression.  Methods: Using the dexamethasone/cortico-
trophin-releasing hormone (DEX/CRH) test, we investigated 
the association of   2 -adrenoceptor (ADRA2A –1291C ] G) 
and the   2 -adrenoceptor gene (ADRB2 Arg16Gly) in 189 pa-
tients with major depression during the acute state of the 
disease and after remission.  Results: Male ADRA2A –1291G 
allele homozygotes showed significant pretreatment HPA 
axis hyperactivity, with increased adrenocorticotropin 
(ACTH; F = 4.9, d.f. = 2, p = 0.009) and cortisol responses (F = 
6.4, d.f. = 2, p = 0.003). In contrast, female ADRB2 Arg/Arg 
homozygotes had increased pretreatment ACTH (F = 7.17,
d.f. = 2, p = 0.001) and cortisol (F = 8.95, d.f. = 2, p = 0.000) 
levels. Interestingly, in the respective genotypes, the stress 
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within the HPA and the closely related sympatho-adre-
nal-medullary (SAM) axes might have tremendous ef-
fects on both the central nervous and cardiovascular sys-
tems. Today, there is no doubt about the deleterious ef-
fects of a comorbidity between depression and coronary 
artery disease, with about a 3-fold increase in morbidity 
and mortality  [4] . One of the repeatedly discussed com-
mon pathophysiological mechanisms for this comorbid-
ity is the impact of stress and the neuroendocrine hor-
mones on the different organs  [4] .
 Stressful life events activate the HPA axis and the ad-
renergic and autonomic nervous systems with lots of in-
teractions between them at different levels  [5] . The sym-
pathetic and CRH neurons are reciprocally connected, 
and thus contribute to the body’s response to stressful 
stimuli. As CRH further alters the noradrenergic activity 
in locus coeruleus neurons, dysfunction of catecholamin-
ergic neurons has been implicated in the pathophysiology 
of affective and stress-related disorders  [6] . 
 Alterations in the HPA axis may be revealed in the 
combined DEX/CRH test demonstrating insufficient 
cortisol suppression and increased ACTH release in a sig-
nificant proportion of depressed patients  [7] . As these al-
terations partially persist after successful treatment with 
remission and abnormal levels of ACTH may be observed 
even in asymptomatic first-degree relatives of depressed 
patients  [8] , a genetic contribution to the regulation of the 
HPA axis has been suggested. 
 Among the candidate genes determining the interac-
tion and regulation of both systems, those involved in the 
regulation of catecholamine function may be of particu-
lar importance. Common single nucleotide polymor-
phisms (SNPs) in adrenergic receptor genes were shown 
as susceptibility loci for obesity, metabolic alterations  [9] 
and cardiovascular disorders  [10] . Further, dysfunctions 
in the noradrenergic system might comprise a significant 
vulnerability trait to develop depression  [11] . The   2 -ad-
renoceptors (ADRA2A) are not involved in the control of 
the HPA axis under basal conditions but exert an inhibi-
tory effect as a negative feedback mechanism, and thus 
limit excessive activation  [12] . Recently, a –1291C ] G 
polymorphism in the promoter region of the ADRA2A 
gene was associated with subnormal cortisol response to 
dexamethasone and elevated glucose levels, suggesting a 
genetic impact on the SAM-HPA axis interaction  [13] . 
Another gene of interest is that coding for the   2 -adreno-
ceptor (ADRB2), as the secretion of ACTH in the ante-
rior pituitary is stimulated by noradrenaline via this re-
ceptor  [14] . A common polymorphism in the ADRB2 
gene causes a change in the amino acids at residues 16 
(Arg16Gly), which has been associated with a 5-fold in-
crease in receptor sensitivity  [15] . The Arg16 allele was 
related to hypertension and obesity in 1 study  [16] , asso-
ciated with the Gly allele in another  [17] , and no relation 
with either of the alleles was observed in another  [18] .
 As discussed, chronic stress induces activation of the 
HPA and SAM axes leading to cardiovascular disease and 
depression in genetically susceptible individuals  [19] . As 
there are several interactions between these 2 axes via   - 
and   -adrenoceptors, we investigated the effects of the 
ADR2A (–1291C ] G) and ADRB2 (Arg16Gly) polymor-
phisms using the combined DEX/CRH test in patients 
with major depression.
 Methods 
 Patients 
 One hundred and eighty-nine (86 males, 103 females, mean 
age 47.5  8 13.1 years) suffering from a major depressive episode 
according to DSM-IV criteria were enrolled in the study. Patients 
with major medical disorders, addictions or other comorbid psy-
chiatric disorders were excluded. In 2.5% of the patients, hyper-
tension was known and the patients were continuously treated 
with anti-hypertensive medication. All patients were white Cau-
casians of German descent.
 Pretreatment with carbamazepine, depot antipsychotics, hor-
mone replacement therapy or fluoxetine were further exclusion 
criteria to avoid interference with endocrinological testing. None 
of the female patients were taking oral contraceptives. The sever-
ity of depression was assessed with the 17-item Hamilton Rating 
Scale for Depression (HRSD-17) by experienced psychiatrists who 
were blind to hormonal measurements and genotyping. Patients 
received either various classes of psychopharmacological drugs or 
non-pharmacological therapies as an acute treatment. These in-
cluded repetitive transcranial magnetic stimulation (25.2%), elec-
troconvulsive therapy (13.0%), tricyclic (12.2%) or non-tricyclic 
antidepressants (50.4% mirtazapine, 13.0% selective serotonin-
reuptake inhibitors, 7.0% venlafaxine, 0.9% moclobemide) and 
combinations; 26.1% received neuroleptics due to mood-congru-
ent psychotic features. Laboratory parameters and clinical vari-
ables such as blood pressure, heart rate and body mass index were 
monitored in all patients at the time of the first DEX/CRH test, 
and in 86 of them at the second DEX/CRH test. Clinical and de-
mographic characteristics of the depressed patients at admission 
are presented in  table 1 .
 The study was carried out according to the Declaration of Hel-
sinki (http://www.wma.net) and had been approved by the local 
ethics committee. After a complete description of the study to the 
subjects, written informed consent was obtained. 
 Combined DEX/CRH Test 
 In all patients, the combined DEX/CRH suppression test was 
performed, following a washout period of at least 5 days after ad-
mission. Participants received 1.5 mg DEX at 23: 00 h. On the fol-
lowing day, an intravenous catheter was inserted before 14: 15 h 
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and blood samples were collected at 15: 00, 15: 15, 15: 30, 15: 45,
16: 00 and 16: 15 h, immediately centrifuged and stored at –80  ° C 
for cortisol and ACTH measurements. At 15: 00 h, 100   g human 
corticotropin-releasing hormone (hCRH; Clinalfa, Läufelfingen, 
Switzerland) were injected within 30 s. Serum cortisol levels were 
determined with an immunoassay analyzer (Elecsys Cortisol 
Test; Roche Diagnostics, Mannheim, Germany) and ACTH plas-
ma concentrations with a commercially available immunoradio-
metric assay (ACTH 100T Kit; Nichols Institute Diagnostics, San 
Juan Capistrano, Calif., USA). In 170 of the patients, the DEX/
CRH test was rerun before discharge from hospital.
 Genotyping of ADR2A –1291C ] G and ADRB2 Arg16Gly 
Polymorphisms 
 Genomic DNA was isolated from whole blood according to 
standard procedures. Genotyping of the ADRB2 polymorphism 
(Arg16Gly, rs1042713) was performed by the fluorescence reso-
nance energy transfer method using the Light Cycler System 
(Roche Diagnostics). The following conditions were applied: for-
ward primer: 5  -GAC AAG CTG AGT GTG CAG GA-3  ; reverse 
primer: 5  -AAC TTG GCA ATG GCT GTG AT-3  ; donor hybrid-
ization probe: 5  -CGT CAC GCA GCA AAG GGA-fluorescein-3  ; 
acceptor hybridization probe: 5  -LCRed640-AGG TGT GGG 
TGG TGG GCA TGG GCA RCG TCA TGT-3  . PCR was per-
formed with 50 ng DNA (total volume 20   l) containing 2   l re-
action mix, 0.5   M each primer, 0.2   M each hybridization probe 
and 2   M MgCl 2 according to the manufactures instructions for 
35 cycles of denaturation (95 ° C, 0 s, ramp rate 20 ° C/s), annealing 
(65 ° C, 10 s, ramp rate 20 ° C/s) and extension (72  ° C, 10 s, ramp 
rate 20 ° C/s). After amplification, a melting curve was generated 
by holding the reaction at 40 ° C for 20 s and then heating slowly 
to 95 ° C with a ramp rate of 0.2 ° C/s. The fluorescence signal was 
plotted against temperature to give melting curves for each sam-
ple. The following peaks were obtained: 61 ° C for the A allele 
(Arg) and 50 ° C for the G allele (Gly). The –1291C ] G SNP in the 
ADRA2A (rs1800544) gene was detected as a restriction fragment 
length polymorphism, as described by Rosmond et al.  [13] . The 
genotyping results were checked by comparison with published 
genotype and allele frequencies from the literature. Moreover, 
each genotyping was performed with internal controls from the 
Table 1. Demographic, clinical characteristics and ADRA2A –1291C]G and ADRB2 Arg16Gly genotypes in patients with major de-
pression, according to gender
All patients 
(n = 189)
Males 
(n = 86)
Females 
(n = 103)
Significance
(males vs. females)
Age, years 47.5813.1 46.9812.2 47.9813.8 n.s.
HRSD-17, week 0 25.185.8 24.885.6 25.286.0 n.s.
HRSD-17, discharge 8.585.0 8.384.8 8.685.2 n.s.
Duration of inpatient status, days 72.1845.4 73.3836.9 70.9851.4 n.s.
Weight, kg 72.8813.4 78.7812.3 67.4812.1 Z = –5.1, p = 0.000
BMI 24.983.9 25.383.6 24.584.1 n.s.
Systolic BP, mm Hg 133.6817.6 135.58817.3 131.8817.8 n.s.
Diastolic BP, mm Hg 87.7810.9 85.2810.9 84.5811.0 n.s.
Heart rate, beats/min 85.7812.8 85.5811.6 86.8813.9 n.s.
Cholesterol, mg/dl 221.4842.3 221.4843.3 221.5841.8 n.s.
Triglycerides, mg/dl 139.1879.8 164.2894.22 118.8859.3 Z = –2.7, p = 0.005
Fasting glucose, mg/ml 99.35821.65 101.5822.1 97.6821.4 n.s.
Cortisol (1st DEX/CRH test: AUC), ng/ml 294.498304.0 281.78277 305.18325.5 n.s.
ACTH (1st DEX/CRH test: AUC), pg/ml 1,128.181,083.9 1,228.481,141.8 1,044.481,031.4 n.s.
ADRA2A –1291C]G
C/C
C/G
G/G 
117 (62.9)
61 (32.3)
11 (5.9)
51 (59.3)
29 (33.7)
6 (7.0)
66 (64.1)
32 (31.1)
5 (4.9)
n.s.1
Frequency C, %
Frequency G, %
78
22
76
24
80
20
n.s.2 
ADRB2 Gly16Arg
Gly/Gly
Gly/Arg
Arg/Arg
74 (39.2)
89 (47.1)
26 (13.8)
32 (37.2)
42 (48.8)
12 (14)
42 (40.8)
47 (45.6)
14 (16.6)
n.s.1
Frequency Gly, %
Frequency Arg, %
63
37
62
38
64
36
n.s.2
Figures in parentheses are percentages. AUC = Area under the curve.
1 2 test. 2 Fisher’s exact test.
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previous experiments. Therefore, we can exclude genotyping er-
rors to a very high degree. With this approach, error rates were 
smaller than 1%. These samples were excluded from the analysis. 
The call rates were greater than 98%. All laboratory procedures 
were carried out blind to case control status.
 Statistical Analyses 
 Deviation from Hardy-Weinberg equilibrium was tested using 
a   2 test (1 d.f.). Differences in genotype and allele frequencies 
between patients and controls and between genders were calcu-
lated with the   2 test and Fisher’s exact test, respectively. Mean 
differences in demographic and clinical variables between males 
and females were compared using the non-parametric Mann-
Whitney test. To evaluate significant time effects on cortisol and 
ACTH concentrations during the DEX/CRH test, ANOVAs for 
repeated measurements were performed using ‘time’ (repeated 
hormonal measurements at the time points 15: 00, 15: 15, 15: 30,
15: 45, 16: 00 and 16: 15 h) as the within-subjects factor with 6 lev-
els, genotypes as the between-subjects factor with 3 levels and age 
as a covariate. To approach normality and homogeneity in the 
data, hormonal concentrations were transformed with the log 
transformation before entering the analysis. Mean differences for 
cortisol and ACTH area under curve (AUC) values as well as sev-
eral clinical characteristics, such as blood pressure, heart rate and 
serum lipids between different genotypes were compared using 
the non-parametric Kruskal-Wallis test. The level of significance 
was set at 0.05. Statistical analysis was performed using SPSS for 
Windows (release 15.0; SPSS, Chicago, Ill., USA).
 Results 
 We carried out the combined DEX/CRH test in 189 pa-
tients with an acute episode of major depression after ad-
mission to the hospital, and repeated this investigation in 
170 of them before discharge. The ACTH and cortisol val-
ues were correlated with clinical variables; in addition, dif-
ferences in dependency of the genotypes of the ADRA2A 
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 Fig. 1. Mean serum cortisol and ACTH concentrations in the 
DEX/CRH test in male and female patients with major depression 
in relation to the ADRA2A –1291C ] G polymorphism. DEX/
CRH tests were performed twice, during the acute state of depres-
sion (86 males, 103 females) and before discharge from hospital 
(77 males, 93 females). Repeated measurement ANOVA of the 
pretreatment DEX/CRH test showed in 6 male –1291GG carriers 
a significant increase in cortisol levels (F = 6.4, d.f. = 2, p = 0.003) 
and ACTH – AUC levels (Kruskal-Wallis test:   2 = 7.3, d.f. = 2,
 * p = 0.026), which remained elevated in the last DEX/CRH test, 
before discharge. In the male CG (n = 29) and CC (n = 51) carriers 
there was no significant difference concerning the cortisol and 
ACTH values. Also in 103 females there was no significant rela-
tion between genotypes and the parameters of the DEX/CRH 
test. 
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–1291C ] G and the ADRB2 Arg16Gly polymorphisms 
were investigated. All genotypes were in Hardy-Weinberg 
equilibrium and the genotype and allele frequencies were 
similar to those reported earlier  [13, 15] ( table 1 ), without 
gender differences for both polymorphisms. 
 The mean HRSD-17 score dropped from 25.1  8 5.8 to 
8.5  8 5.0 between the first and the second DEX/CRH test 
( table 1 ), which means a 66% overall reduction in depres-
sive symptoms. Assuming a minimum of 50% score re-
duction as response criterion, 82.4% of the patients may 
be classified as responders at the time of discharge from 
hospital. We could not observe gender differences con-
cerning the severity of symptoms (HRSD-17) or the dura-
tion of inpatient status, blood pressure and heart rate. 
Concerning weight and serum triglycerides, we observed 
significantly higher values in the male patient group at 
the time of hospitalization. Basal and stimulated cortisol 
and ACTH levels of the first DEX/CRH test (both ex-
pressed as AUC did not vary significantly between males 
and females;  table 1 ).
 Using ANOVA for repeated measurements, signifi-
cant effects in the DEX/CRH test results could be dem-
onstrated. In the total patient group, there were signifi-
cant ‘time’ effects for both ACTH (F = 56.4, d.f. = 2, p  ! 
0.001) and cortisol (F = 76.9, d.f. = 2, p  ! 0.001), indicat-
ing significant increases in HPA axis hormones after 
hCRH injection. 
 These effects were further influenced by the different 
genotypes investigated. The pretreatment DEX/CRH test 
(repeated-measures ANOVA) showed, in the 6 male pa-
tients homozygous for the ADRA2A –1291G allele, a sig-
nificant increase in cortisol ( fig. 1 : F = 6.4, d.f. = 2, p = 
0.003) and ACTH (F = 4.9, d.f. = 2, p = 0.009) response. 
Correspondingly, the cortisol AUC levels in males were 
762  8 475 ng/ml in GG genotypes, 293  8 242 ng/ml in 
GC genotypes and 218  8 207 ng/ml in CC genotypes 
(Kruskal-Wallis test:   2 = 9.04, d.f. = 2, p = 0.011). Only 1 
of these GG carriers had a cortisol AUC value in the mean 
range of the CG and CC genotypes (220 ng/ml); in the 
other five ADRA2A-GG patients, the cortisol AUC val-
ues ranged from 400 to 1,480 ng/ml. Also, the ACTH 
AUC values were significantly elevated in the male GG 
genotypes (2,566  8 1,770 pg/ml), in contrast to the GC 
(1,195  8 927 pg/ml) and CC carriers (1,007  8 1,012 pg/
ml; Kruskal-Wallis test:   2 = 7.29, d.f. = 2, p = 0.026). In-
terestingly, the cortisol AUCs remained significantly el-
evated in the male GG carriers at the time of discharge 
from hospital (  2 = 7.09, d.f. = 2, p = 0.029). In contrast, 
in the female patient group (n = 108) we observed no sig-
nificant relation between the ADRA2A genotypes and 
the time effects of ACTH or cortisol before treatment 
(ACTH: F = 0.011, d.f. = 2, p = 0.98; cortisol: F = 0.095, 
d.f. = 2, p = 0.90) or before discharge (ACTH: F = 0.017, 
d.f. = 2, p = 0.98; cortisol: F = 0.26, d.f. = 2, p = 0.77).
 Concerning the ADRB2 Arg16Gly polymorphism, we 
found increased HPA axis activity using repeated-mea-
sures ANOVA in females carrying at least one 16Arg al-
lele, with highest pretreatment ACTH (F = 7.17, d.f. = 2, 
p = 0.001) and cortisol curves (F = 8.95, d.f. = 2, p = 0.000) 
in Arg/Arg genotypes ( fig. 2 ). The cortisol and AUC val-
ues were 575  8 140 ng/ml in Arg/Arg genotypes, 356  8 
321 ng/ml in Arg/Gly genotypes and 188  8 250 ng/ml in 
Gly/Gly genotypes (Kruskal-Wallis test:   2 = 15.8, d.f. = 
2, p = 0.000). ACTH values were: 1,775  8 1,291 pg/ml in 
Arg/Arg genotypes, 1,283  8 1,208 pg/ml in Arg/Gly and 
683  8 806 pg/ml in Gly/Gly genotypes (Kruskal-Wallis 
test   2 = 14.3, d.f. = 2, p = 0.001). Although the overall 
values were slightly decreased in the last observation, 
there was still a significant effect of the ADRB2 Arg16Gly 
polymorphism in female, but not in male, patients (ACTH: 
F = 4.31, d.f. = 2, p = 0.017; cortisol: F = 5.57, d.f. = 2, p = 
0.005). In males, no genotype related differences were ob-
served for the ACTH DEX/CRH (F = 2.04. d.f. = 2, p = 
0.114) or cortisol curves (F = 1.86, d.f. = 2, p = 0.162). In 
 table 2 some clinical data are listed in relation to the 
ADRA2A –1291C ] G and ADRB2 Arg16Gly genotypes. 
We were unable to identify any association between gen-
otypes and the baseline levels of BMI, serum lipids, fast-
ing glucose, blood pressure or heart rate. In 45% (n = 86) 
of the patients, these clinical parameters were again mon-
itored at the time of the second DEX/CRH test, but no 
significant differences were obtained between the first 
and second measurement, and again there was no rela-
tion to the investigated genotypes. Although we observed 
a slight increase in the BMI from 24.9  8 3.8 to 25.1  8 
4.2, this failed to reach significance. We observed a small 
but significant correlation between the cortisol AUC val-
ues of the pretreatment DEX/CRH test to the baseline 
HRSD-17 values (Spearman’s correlation:   = 0.157, p = 
0.035). After Bonferroni correction for multiple testing, 
only a non-significant trend to the relatively weak corre-
lation could be detected. In males homozygous for the 
ADRA2A –1291G allele, a mean decrease of only 41.2% 
in HRSD-17 score was observed, compared to decreases 
of 70.3 and 64.0% in the CG and CC genotypes, respec-
tively, but this finding failed to reach significance (Krus-
kal-Wallis test   2 = 4.1, d.f. = 2, p = 0.12), probably due to 
the low number of GG patients. There were no other clin-
ical variables which differentiated the male ADRA2A 
GG carriers from the other patients. 
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 In the female patient group, there was no relation be-
tween the ADRA2A genotypes and treatment response 
(Kruskal-Wallis test   2 = 1.0, d.f. = 2, p = 0.57) and an 
overall response of about a 65% reduction in depressive 
symptoms was observed in all genotypes. Concerning the 
ADRB2 genotypes and the response to treatment, there 
was no relation to treatment response in the male or fe-
male patient group ( table 2 ).
 In order to differentiate between pre- and post-meno-
pausal women, we split the female patients into those be-
low 50 years of age (n = 54) and those above 50 years (n = 
49). No significant differences between these 2 groups 
were observed concerning the distribution of the ADRB2 
Arg16Gly genotypes (  2 = 0.29, d.f. = 2, p = 0.86), the se-
verity of baseline depressive symptoms or the response to 
treatment. However, we observed significant differences 
in systolic (Z = –3.11, p = 0.002) and diastolic blood pres-
sure (Z = –3.93, p = 0.04) as well as in serum cholesterol 
(Z = –3.93, p = 0.000) and triglyceride values (Z = –2.29, 
p = 0.022), with higher values in women above 50 years 
of age (systolic blood pressure,  ! 50 years: 125  8 19 mm 
Hg,  1 50 years: 136  8 16 mm Hg; diastolic blood pres-
sure,  ! 50 years: 201  8 39 mg/dl,  1 50 years: 235  8 30 
mg/dl; triglycerides,  ! 50 years: 102  8 47 mg/dl,  1 50 
years: 129  8 49 mg/dl). Concerning the ACTH and cor-
tisol curves, we observed higher values in the pretreat-
ment DEX/CRH test in women beyond the age of 50 
years, which, however, just failed significance (ACTH:
F = 3.08, d.f. = 2, p = 0.082; cortisol: F = 2.94, d.f. = 2,
p = 0.089). At the time of the second Dex/CRH test, there 
was no relation between the ACTH and cortisol curves 
and the age being below or above 50 years in females. 
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 Fig. 2. Mean serum cortisol and ACTH concentrations in the 
DEX/CRH test in male and female patients with major depression 
in relation to the ADRB2 Gly16Ser polymorphism. DEX/CRH 
tests were performed twice, during the acute state of depression 
(86 males, 103 females) and before discharge from hospital (77 
males, 93 females). Repeated measurement ANOVA of the pre-
treatment and the last DEX/CRH test showed no significant rela-
tion between genotypes and hormone concentrations in male pa-
tients. In females carrying at least one 16Arg allele (n = 61), HPA 
axis activity was increased, with highest pretreatment cortisol re-
sponse (repeated measurement ANOVA: F = 8.9, d.f. = 2, p = 
0.000) and ACTH-AUC values in Arg/Arg genotypes (Kruskal-
Wallis test:   2 = 13.9, d.f. = 2,  * p = 0.001). The overall ACTH AUC 
values and cortisol response curves were slightly decreased in the 
last observation but still significantly elevated in female Arg/Arg 
genotyopes (ACTH:   2 = 10.8, d.f. = 2,  * * p = 0.004; cortisol: F = 
5.5, d.f. = 2, p = 0.005). 
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 Discussion 
 With respect to the multiple interactions between the 
sympathetic nervous system and the HPA axis, we inves-
tigated 2 polymorphisms in the ADRA2A and the ADRB2 
genes in relation to the ACTH and cortisol values of the 
DEX/CRH test in patients with major depression. 
 The major and unexpected findings of our study were 
gene-gender effects in the associations between adren-
ergic polymorphisms and HPA axis activity. Males ho-
mozygous for the ADRA2A –1291G allele showed in-
creased ACTH and cortisol responses in the DEX/CRH 
test, both in the acute state of the disease and before dis-
charge from hospital. In contrast, no effect of the 
ADRA2A polymorphism on basal or hCRH-stimulated 
ACTH and cortisol values could be observed in the fe-
male patient group. Concerning the ADRB2 Arg16Gly 
polymorphism, we found increased HPA axis activity in 
females carrying at least one 16Arg allele, with highest 
pretreatment ACTH and cortisol values in Arg/Arg ho-
mozygotes, and this increased response remained ele-
vated before discharge from hospital. This study thus 
provides evidence that, depending on gender and geno-
types in   - and   - drenoceptor genes, there might be a 
continuous HPA axis overdrive with increased ACTH 
and cortisol secretion, irrespectively of the actual status 
of depression.
 There is no doubt that persistent alterations in corti-
sol exposure could result in target tissue pathology as 
occurs in chronically stressed or depressed individuals 
 [1] . While the role of stress and the consecutive hyper-
activity of the HPA axis is well established  [7, 20] , there 
is also recent evidence that high HPA axis reactivity to 
stress and increased tissue sensitivity to cortisol are as-
sociated with severe atherosclerosis  [21] . Due to several 
studies, there is convincing evidence that the depresso-
genic effect of stress has some genetic underpinning, as 
carriers of the 5-HTTLPR S allele are more likely to de-
velop depression in response to a stressful life event  [22, 
23, 20] . Another study has shown that among patients 
with chronic illness, carriers of the S allele are more vul-
nerable to depression, perceived stress and high norepi-
Table 2. Clinical data in relation to the ADRA2A –1291C]G and ADRB2 Arg16Gly polymorphisms
HRSD-17
basal score
HRSD-17
decrease, %
BMI Cholesterol
mg/dl
Triglycerides
mg/dl
Systolic BP
mm Hg
Diastolic BP
mm Hg
HR, beats/
min
ADRA2A –1291C]G
All patients (n = 189)
CC
CG
GG
25.585.9
24.885.5
24.786.8
63.4823.1 
69.3817.3
53.2833.0
25.283.9
24.584.1
25.284.2
222838
220848
240832
130865
150895
137871
132818
131818
132820
82810
82810
80811
83812
84810
8289
n.s F = 3.1; p = 0.044 n.s. n.s. n.s. n.s. n.s. n.s.
Males (n = 86)
CC
CG
GG
25.285.7
24.684.8
22.386.3
64.1823.2
70.39815
41.2839
25.983.4
25.084.1
24.083.1
228837
206848
251830
160876
177886
158848
134818
133818
129819
8289
8389
81810
81814
8489
8189
n.s. F = 4.6; p = 0.012 n.s. n.s. n.s. n.s. n.s. n.s.
ADRB2 Arg16Gly
All patients (n = 189)
Gly/Gly
Gly/Arg
Arg/Arg
25.385.8
24.585.8
26.985.3
66.2824.4
62.9820.6
65.6822.2
25.281.1
24.684.2
25.583.4
220846
222839
226846
132867
141889
147870
134816
128818
134816
8488
78811
8489
83812
83810
84812
n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s.
Females (n = 103)
Gly/Gly
Gly/Arg
Arg/Arg
26.186.0
24.586.4
27.284.6
67.4821.3
62.0821.6
66.5821.3
25.184.8
23.484.2
24.782.0
223844
218841
229849
116849
108854
158887
133817
125818
139819
8488
78816
86811
84811
8389.2
88812
n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s.
Data are presented as means 8 SD. BP = Blood pressure; HR = heart rate.
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nephrine secretion, and these factors may contribute to 
or worsen cardiovascular outcomes  [24] . Although gen-
der is increasingly perceived as key determinant in var-
ious disorders, systematic studies are still scarce. Con-
cerning hormonal response patterns of the HPA axis, 
some recent papers pointed to gender differences in the 
reactivity to stress. Thus, it was shown by Heim et al. 
 [25] that men with childhood trauma and current major 
depression exhibited increased ACTH and cortisol re-
sponses in the DEX/CRH test compared with non-
abused men. It was further demonstrated that male sub-
jects had a greater HPA axis response to a psychological 
stressor than female subjects, whereas women had a 
greater hormonal reactivity to pharmacologic stimula-
tion  [26] . Sex differences in ACTH pulsatility following 
metapyrone blockade were observed in another study, 
with men showing smaller ACTH AUCs than women 
 [27] . The fact that highly anxious females exhibited low-
er cortisol release than highly anxious males further 
suggested that high trait anxiety females may be associ-
ated with an inability to respond with sufficient activa-
tion of the HPA axis under acute psychological stress 
 [28] . Our observation that the ADRA2A and ADRB2 
genotypes have differential effects on HPA axis func-
tion in males and females might be seen in context of the 
recent data. One possible explanation for the gene-gen-
der interaction could be estrogen, a hormone which in-
fluences the activity of the HPA and SAM axes. Between 
puberty and menopause, women usually show lower 
HPA axis activity and autonomic responses than men of 
the same age. However, the response is higher in the lu-
teal phase, when post-stress free cortisol levels ap-
proaches those of men. After menopause, there is an in-
crease in sympathoadrenal responsiveness, and conse-
quently estrogen replacement therapy reduces HPA 
activity and sympathetic nervous system activity  [29] . 
Although in our study, we did not monitor the hormon-
al phases within the female cycle and we did not exactly 
distinguish between females being in the pre- or post-
menopausal phase, we calculated the data separately for 
women below and above the age of 50 years. As expect-
ed, we found significantly increased systolic and dia-
stolic blood pressure and triglyceride serum levels in
the older group. We further found increased levels of 
ACTH and cortisol in the DEX/CRH test in females be-
yond 50 years. However, the fact that this difference was 
of marginal significance (p = 0.08), the observed gene-
gender effect of the ADRB2 Arg16Gly polymorphism
is not likely to be explained by different levels of estro-
gen. Several limitations may be noted in this study. 
Firstly, the number of male patients homozygous for the 
ADRA2A –1291G allele is rather low (6.9%), and, in con-
sequence, the explanatory power is not high. However, 
this low number is outweighed by the huge difference
in the ACTH and cortisol values in GG homozygous 
males (peak ACTH = 51.3 pg/ml; peak cortisol = 10.4 
ng/ml) as compared to the GC and CC genotypes (peak
ACTH = 18.8 pg/ml; peak cortisol = 4.2 ng/ml). Further, 
and maybe of more importance, is the fact that the HPA 
axis hyperactivity was not downregulated during treat-
ment, thus indicating a continuously increased ACTH 
and cortisol outflow with all its consequences on me-
tabolism, the vasculature and the immune system. A 
further limitation of our study is the fact that we did not 
consecutively follow up several physiological parame-
ters such as weight, blood pressure and serum lipids in 
all patients, and thus we are unable to relate the poly-
morphisms reliably to these parameters. Moreover, 
many of the patients had been pretreated (despite a 
washout period of 5 days), and thus both the serum lip-
ids and weight might have been altered. 
 In conclusion, although preliminary, our findings 
demonstrate the potential of genetic effects on the stress 
response system in pathological conditions such as de-
pression. The ADRA2A –1291GG genotype was associ-
ated with increased HPA axis activity in men and the 
ADRB2 Arg allele with that in females. The fact that in 
carriers of the respective allele the increased ACTH and 
cortisol values remained elevated in remission provides 
evidence that, depending on gender and the polymor-
phisms, there might be continuous HPA axis overdrive. 
Considering the importance of cortisol in atherosclero-
sis, one might be tempted to hypothesize that these pa-
tients are at high risk of comorbidity between depression 
and cardiovascular disorders. In future, prospective stud-
ies including both patients groups are clearly warranted.
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